Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Bullboard (CSE:AGN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by EricSnotton Jun 25, 2023 2:43pm

AGN @ .04 (without the Reverse SPlit)....nothing here but

blah blah blah from Chris! Not going back to preCovid prices, mates!!!!!!!
113
Post by SkywalkerofLukeon Jun 06, 2023 3:36pm

Ifenprodil News

After announcing yesterday AGN.c AGNPF completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of DMT, they announced today they will be presenting their ...more  
170
Post by SkywalkerofLukeon Jun 05, 2023 3:28pm

CEO Interview on Phase 2 Stroke and TBI Study

AGN.c AGNPF is the world’s first company to investigate DMT for both the treatment of stroke and traumatic brain injury (global stroke treatment market expected to Reach a Value of $15B by the Year ...more  
165
Post by SkywalkerofLukeon Jun 01, 2023 5:53pm

CEO on Recent News

A recent study found that Chronic Kidney Disease affects “as many as 40% of the elderly population in Canada and other developed countries” = a large addressable market for AGN.c AGNPF who were ...more  
163
Post by SkywalkerofLukeon May 31, 2023 3:42pm

News

Big step forward for small cap health tech company AGN.c AGNPF who’s up 10% coming off the announcement they were granted a patent in Japan for Treating Chronic Kidney Disease with drug NP-251 or ...more  
178
Post by XeniaTechieon May 26, 2023 3:00pm

Chris discusses recent notice of allowance

Exciting news from Algernon Pharmaceuticals as they’ve made significant progress in drug development while securing additional funding. Recent NOA from USPTO and successful rights offering further ...more  
182
Post by SkywalkerofLukeon May 25, 2023 3:28pm

Clip w/ CEO

Here’s a clip w/ the AGN.c AGNPF CEO discussing their subsidiary Algernon NeuroScience and the work they’re doing with DMT for stroke and traumatic brain injury treatments. The stroke treatment ...more  
122
Post by DIYPortfolio57on May 24, 2023 6:16pm

AGN is having positive results using DMT to treat stroke

https://www.youtube.com/watch?v=usgU9aPFzXU
132
Comment by quicksilver545on May 20, 2023 1:38pm

RE:RE:Update on Intravenous DMT Study

They are positioned in some unique markets for sure, but to say they are well funded is not true. They didn't reach 50% of the funds they were hoping to raise through the rights offering. 
78
Discussion
Comment by waves1on May 18, 2023 2:32pm

RE:Update on Intravenous DMT Study

It's notable that AGN is positioned in a few unique markets with little to no competitors. Plus, as AGN just raised over $1.18M from a rights offering, they should be well funded going forward ...more  
111
Discussion
Post by SkywalkerofLukeon May 15, 2023 4:44pm

Update on Intravenous DMT Study

The stroke treatment market is est. to reach value of $15B by 2027 & the global traumatic brain injury market is projected to grow from 3.1B to 4.5B by 2026. AGN.c AGNPF is working to address ...more  
182
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities